AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Essential Maintenance
: All Authorea-powered sites will be offline 9am-10am EDT Tuesday 28 May
and 11pm-1am EDT Tuesday 28-Wednesday 29 May. We apologise for any inconvenience.
Erkan Cure
Public Documents
1
Comment on “ACE inhibitors and COVID-19: We don’t know yet”
Tevfik Ilcol
and 2 more
May 04, 2020
We read with great interest the article by Khashkhusha TR et al “ACE inhibitors and COVID-19: We don’t know yet”. The authors discuss whether the use of angiotensin-converting enzyme (ACE) inhibitors (ACEIs) in novel coronavirus disease‐19 (COVID‐19) patients is beneficial or harmful. ACEIs and angiotensin receptor antagonists (ARBs) both upregulate ACE2 levels. We believe that ARBs should be preferred since, unlike ARBs, ACEIs may increase angiotensin II through the chymase pathway. We would like to discuss potential harms ACEI may cause through secondary bradykinin-chymase pathways.